# Alto Neuroscience Inc. (ANRO) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Biotechnology. Price $35.55, market value $1.4 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Alto Neuroscience Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 5.7×**. The shares trade at 5.7× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -4.9%** (5-yr avg -28.8%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -41.8%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 12.4%**. Earnings per share rose 12.4%.

## Financial health
- **Debt to equity: 0.11**. Debt is 0.11 times equity: a conservative balance sheet.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Alto Neuroscience Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (10 analysts). 10 analysts cover Alto Neuroscience Inc.; the consensus is strong_buy, with an average price target of $38.38 (+8% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 912.8%** (YTD 99.7%, 3-mo 94.7%). The shares are up 912.8% over twelve months including dividends.
- **From 52-week high: -5.1%** (915.7% above the low). Trading 5% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 64**. An RSI of 64 is neutral.
- **Beta (1 yr): 2.27** (volatility 128%). Beta of 2.27 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ANRO · Page: https://foliofundamentals.com/stocks/anro

Not investment advice.